Lymphocytic colitis in the setting of teriflunomide use for relapsing multiple sclerosis. (November 2020)

• Record Type: Journal Article
• Authors: Son, Maksim; McEwan, Lynn; Ubaidat, Manaf; Bovell, Keith; Morrow, Sarah A
• Is Part Of: Multiple sclerosis. Volume 26:Number 13(2020)
• Page Start: 1801
• Page End: 1803
• Publication Date: 2020-11
• Subjects: Teriflunomide -- colitis -- multiple sclerosis -- lymphocytic; Central nervous system -- Diseases -- Periodicals; Myelin sheath -- Diseases -- Periodicals; Inflammation -- Periodicals; Multiple sclerosis -- Periodicals; Central Nervous System Diseases -- Periodicals; Demyelinating Diseases -- Periodicals; Inflammation -- Periodicals; Multiple Sclerosis -- Periodicals; Système nerveux central -- Maladies -- Périodiques; Gaine de myéline -- Maladies -- Périodiques; Inflammation (Pathologie) -- Périodiques; Sclérose en plaques -- Périodiques; Electronic journals; 616.834005
• DOI: 10.1177/1352458519900961
• Languages: English
• ISSNs: 1352-4585

Abstract

Teriflunomide is an oral monotherapy used to treat relapsing multiple sclerosis. Although teriflunomide may be associated with gastrointestinal symptoms, these events are mild and self-limiting. We present a 39-year-old female who developed severe diarrhea and lost 20 pounds within 3 weeks of starting teriflunomide. Despite discontinuing teriflunomide and undergoing cholestyramine washout, her symptoms persisted. Celiac disease on genetic testing was positive, but no anti-transglutaminase and anti-endomysial antibodies were detected. She underwent colonoscopy and biopsy was consistent with lymphocytic colitis. Remission was achieved within days of starting budenoside. Our case describes a rare, but serious, gastrointestinal adverse event of teriflunomide.